knowledge -WSS

knowledge

author：hotspot 2025-08-25 07:30:15 - browse：3186

Moderna chairman Noubar Afeyan exuded star power earlier this month as he commanded the spotlight at BIO 2023, the industry’s largest convention.

Basking in the accolades heaped on Moderna’s celebrated Covid-19 vaccine, Afeyan regaled the Boston audience with the company’s origin story and greeted fans who lined up to snap selfies with him. Stuart Cable, a partner in the law firm Goodwin who’s represented Moderna and joined Afeyan on stage, called Moderna “arguably the most successful story in the history of biotechnology.”

But the Cambridge, Mass.-based company can’t afford to rest on its laurels. Two and a half years after its vaccine liberated tens of millions from pandemic lockdowns — ringing up more than $36 billion in sales so far — Moderna faces a changing business and regulatory environment. Demand for Covid shots is waning, a backlash over drug prices is gaining traction, and questions about its next act loom.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Readout Newsletter: The latest on Moderna, Apellis, and Merck

WSS

More regulation could be coming for drug ads

Judge rejects Trump's counterclaim against E. Jean Carroll

What STAT readers think about the FDA and patient advocacy

Zapping the brain for stroke rehab: Pivotal clinical trial begins

Drinking less cuts risk of oral cavity, esophageal cancer: Report

Discs beat pads, tampons for heavy menstrual flow, new study shows

leisure time

knowledge

knowledge

Duchenne breakthrough therapy leaves behind pioneering families

Medicare Advantage beneficiaries sue Humana over algorithm use

Medicare details structure of new drug price negotiation program

Prime Medicine, Myeloid Therapeutics clash over genome

Jerome Adams on the need for new antivirals for Covid

Mega Millions jackpot estimated at record $1.58 billion for Tuesday's drawing

DIEP, the 'gold standard' of breast reconstruction, is under threat

Germany receives 178 compensation applications from gay servicepeople over discrimination

As demand for Covid shots wanes, Moderna seeks its next success

Prime Medicine, Myeloid Therapeutics clash over genome

knowledge

Virtual care provider acquires bankrupt Pear's prescription apps

Cheesesteak restaurant owner explains his secret sauce, the viral Malibu Barbie Dream Drizzle

Former Georgia lieutenant governor says he received grand jury subpoena

An Ebola outbreak presents a new mystery involving children

Boston man files lawsuit seeking to bankrupt white supremacist group he says assaulted him

In Spain, a hospital brews its own CAR

focus

hotspot

knowledge

focus